vs
OCTAVE SPECIALTY GROUP INC（OSG）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是OCTAVE SPECIALTY GROUP INC的1.1倍（$75.5M vs $66.9M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 2.6%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 16.2%）
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
OSG vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.1倍
$66.9M
营收增速更快
PBYI
高出25.1%
2.6%
两年增速更快
PBYI
近两年复合增速
16.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.9M | $75.5M |
| 净利润 | $-29.7M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | -76.7% | 22.7% |
| 净利率 | -73.8% | — |
| 营收同比 | 2.6% | 27.7% |
| 净利润同比 | -41.7% | — |
| 每股收益（稀释后） | $-0.82 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OSGPBYI
| Q4 25 | $66.9M | $75.5M | ||
| Q3 25 | $66.6M | $54.5M | ||
| Q2 25 | $55.0M | $52.4M | ||
| Q1 25 | $62.8M | $46.0M | ||
| Q4 24 | $65.2M | $59.1M | ||
| Q3 24 | $70.0M | $80.5M | ||
| Q2 24 | $51.0M | $47.1M | ||
| Q1 24 | $49.6M | $43.8M |
净利润OSGPBYI
| Q4 25 | $-29.7M | — | ||
| Q3 25 | $-112.6M | $8.8M | ||
| Q2 25 | $-72.7M | $5.9M | ||
| Q1 25 | $-44.7M | $3.0M | ||
| Q4 24 | $-20.9M | — | ||
| Q3 24 | $-27.5M | $20.3M | ||
| Q2 24 | $-750.0K | $-4.5M | ||
| Q1 24 | $20.8M | $-4.8M |
毛利率OSGPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率OSGPBYI
| Q4 25 | -76.7% | 22.7% | ||
| Q3 25 | -48.2% | 17.6% | ||
| Q2 25 | -41.8% | 12.7% | ||
| Q1 25 | -24.1% | 8.7% | ||
| Q4 24 | -55.5% | 22.6% | ||
| Q3 24 | -29.7% | 27.4% | ||
| Q2 24 | -28.9% | -4.6% | ||
| Q1 24 | -6.5% | -5.3% |
净利率OSGPBYI
| Q4 25 | -73.8% | — | ||
| Q3 25 | -169.1% | 16.2% | ||
| Q2 25 | -132.3% | 11.2% | ||
| Q1 25 | -71.3% | 6.5% | ||
| Q4 24 | -55.1% | — | ||
| Q3 24 | -39.3% | 25.2% | ||
| Q2 24 | -1.5% | -9.6% | ||
| Q1 24 | 41.9% | -11.0% |
每股收益（稀释后）OSGPBYI
| Q4 25 | $-0.82 | $0.26 | ||
| Q3 25 | $-2.35 | $0.17 | ||
| Q2 25 | $-1.54 | $0.12 | ||
| Q1 25 | $-1.22 | $0.06 | ||
| Q4 24 | $-11.75 | $0.40 | ||
| Q3 24 | $-0.63 | $0.41 | ||
| Q2 24 | $-0.02 | $-0.09 | ||
| Q1 24 | $0.44 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.4M | $97.5M |
| 总债务越低越好 | $117.6M | $22.7M |
| 股东权益账面价值 | $715.8M | $130.3M |
| 总资产 | $2.2B | $216.3M |
| 负债/权益比越低杠杆越低 | 0.16× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资OSGPBYI
| Q4 25 | $146.4M | $97.5M | ||
| Q3 25 | $27.5M | $94.4M | ||
| Q2 25 | $22.5M | $96.0M | ||
| Q1 25 | $34.1M | $93.2M | ||
| Q4 24 | $157.2M | $101.0M | ||
| Q3 24 | $40.8M | $96.7M | ||
| Q2 24 | $14.6M | $96.8M | ||
| Q1 24 | $13.8M | $107.2M |
总债务OSGPBYI
| Q4 25 | $117.6M | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $0 | $68.0M | ||
| Q3 24 | $518.0M | $79.3M | ||
| Q2 24 | $515.0M | $90.7M | ||
| Q1 24 | $512.0M | $102.0M |
股东权益OSGPBYI
| Q4 25 | $715.8M | $130.3M | ||
| Q3 25 | $843.4M | $115.3M | ||
| Q2 25 | $859.8M | $104.7M | ||
| Q1 25 | $852.2M | $97.1M | ||
| Q4 24 | $798.4M | $92.1M | ||
| Q3 24 | $1.5B | $71.1M | ||
| Q2 24 | $1.4B | $48.5M | ||
| Q1 24 | $1.4B | $51.0M |
总资产OSGPBYI
| Q4 25 | $2.2B | $216.3M | ||
| Q3 25 | $2.1B | $202.9M | ||
| Q2 25 | $8.5B | $194.9M | ||
| Q1 25 | $8.3B | $196.2M | ||
| Q4 24 | $8.1B | $213.3M | ||
| Q3 24 | $9.3B | $220.7M | ||
| Q2 24 | $8.2B | $205.0M | ||
| Q1 24 | $8.4B | $214.1M |
负债/权益比OSGPBYI
| Q4 25 | 0.16× | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.00× | 0.74× | ||
| Q3 24 | 0.35× | 1.12× | ||
| Q2 24 | 0.38× | 1.87× | ||
| Q1 24 | 0.38× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.3M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流OSGPBYI
| Q4 25 | $-52.3M | $14.4M | ||
| Q3 25 | $-41.2M | $9.7M | ||
| Q2 25 | $2.1M | $14.1M | ||
| Q1 25 | $-12.6M | $3.6M | ||
| Q4 24 | $762.0K | $15.6M | ||
| Q3 24 | $48.9M | $11.0M | ||
| Q2 24 | $20.4M | $1.0M | ||
| Q1 24 | $7.1M | $11.2M |
自由现金流OSGPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率OSGPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度OSGPBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率OSGPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OSG
| Other | $28.7M | 43% |
| Specialty Property Casualty Program | $23.1M | 34% |
| Accident Health | $9.6M | 14% |
| Specialty Automobile | $3.1M | 5% |
| Niche Specialty Risks | $2.4M | 4% |
PBYI
暂无分部数据
